This is a multi-center, single arm, open label phase 3 study to evaluate the safety and efficacy of CM310 in children patients with moderate-to-severe atopic dermatitis.
Eligibility
Sex
ALL
Min age
12 Years
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria:
* Have the ability to understand the study and voluntarily sign a written informed consent form (ICF).
* Subjects who must complete the evaluation of Week 18 of the main study.
* With Atopic Dermatitis.
Exclusion Criteria:
* Any major surgery planned during the research period.
* Subjects with potential fertility do not agree to adopt efficient contraceptive measures throughout the entire study period; Pregnant or breastfeeding women, or women planning to conceive or breastfeed during the study period.
* With any circumstance that the subject is not suitable to participate in this study.
Primary outcome measure(s)
Adverse events — up to week 52 Incidence of adverse events.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.